LT3111954T - Ankilozuojančio spondilito gydymo būdai, naudojant anti-il-17 antikūnus - Google Patents

Ankilozuojančio spondilito gydymo būdai, naudojant anti-il-17 antikūnus

Info

Publication number
LT3111954T
LT3111954T LTEP16163440.7T LT16163440T LT3111954T LT 3111954 T LT3111954 T LT 3111954T LT 16163440 T LT16163440 T LT 16163440T LT 3111954 T LT3111954 T LT 3111954T
Authority
LT
Lithuania
Prior art keywords
antibodies
methods
ankylosing spondylitis
treating ankylosing
treating
Prior art date
Application number
LTEP16163440.7T
Other languages
English (en)
Inventor
Shepard MPOFU
Hanno Richards
Karthinathan Thangavelu
Matthias Machacek
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44906168&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT3111954(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of LT3111954T publication Critical patent/LT3111954T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
LTEP16163440.7T 2010-11-05 2011-11-04 Ankilozuojančio spondilito gydymo būdai, naudojant anti-il-17 antikūnus LT3111954T (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41053310P 2010-11-05 2010-11-05

Publications (1)

Publication Number Publication Date
LT3111954T true LT3111954T (lt) 2019-07-10

Family

ID=44906168

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP16163440.7T LT3111954T (lt) 2010-11-05 2011-11-04 Ankilozuojančio spondilito gydymo būdai, naudojant anti-il-17 antikūnus

Country Status (27)

Country Link
US (9) US9744234B2 (lt)
EP (6) EP2635303A2 (lt)
JP (7) JP2014503482A (lt)
KR (5) KR20160067984A (lt)
CN (2) CN103189074A (lt)
AU (1) AU2011325134B2 (lt)
BR (1) BR112013011176A2 (lt)
CA (2) CA2813849C (lt)
CL (1) CL2013001213A1 (lt)
CY (1) CY1121802T1 (lt)
DE (1) DE20187001T1 (lt)
DK (1) DK3111954T3 (lt)
ES (2) ES2733712T3 (lt)
HR (1) HRP20191162T1 (lt)
HU (1) HUE044038T2 (lt)
IL (4) IL311014A (lt)
LT (1) LT3111954T (lt)
MA (1) MA34647B1 (lt)
MX (1) MX362591B (lt)
PL (1) PL3111954T3 (lt)
PT (1) PT3111954T (lt)
RU (1) RU2582937C2 (lt)
SG (2) SG189138A1 (lt)
SI (1) SI3111954T1 (lt)
TR (1) TR201909531T4 (lt)
TW (3) TWI616204B (lt)
WO (1) WO2012059598A2 (lt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6120767B2 (ja) 2010-05-20 2017-04-26 アブリンクス ナームローゼ・フェノーツハップＡｂｌｙｎｘ ＮＶ Ｈｅｒ３に関連する生物学的材料
ES2733712T3 (es) * 2010-11-05 2019-12-02 Novartis Ag Métodos para tratar la espondilitis anquilosante utilizando anticuerpos anti-IL-17
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
KR102132997B1 (ko) 2011-10-11 2020-07-14 메디뮨 엘엘씨 Cd40l 특이적 tn3 유래 스카폴드 및 이의 사용 방법
EP2809660B1 (en) 2012-02-02 2016-01-20 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating il-17
US20140004131A1 (en) * 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
WO2014155278A2 (en) 2013-03-26 2014-10-02 Novartis Ag Methods of treating autoimmune diseases using il-17 antagonists
JP2016539925A (ja) 2013-10-22 2016-12-22 ノビミューン エスアー Ｔｌｒ４リガンドまたは他のバイオマーカーのレベルが上昇した患者における障害の診断および処置を行うための方法および組成物
US20160340422A1 (en) * 2014-01-28 2016-11-24 Beijing Hanmi Pharmaceutical Co., Ltd. Bifunctional fusion protein, preparation method therefor, and use thereof
SG10201810108PA (en) 2014-05-13 2018-12-28 Medimmune Ltd Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small cell lung cancer
CN107072955B (zh) 2014-05-15 2021-06-18 拉尼医疗有限公司 包含多肽和/或蛋白质的固体块的药物组合物和该固体块的制备方法
US11548940B2 (en) 2014-05-15 2023-01-10 Rani Therapeutics, Llc Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
FR3021976B1 (fr) * 2014-06-06 2018-11-02 Hospices Civils De Lyon Marqueur biologique permettant d'evaluer le niveau pro-inflammatoire dependant de la contribution fonctionnelle de l'il-17 chez un individu
US20160002326A1 (en) * 2014-06-10 2016-01-07 Abbvie Inc. Compositions and methods for treating rheumatoid arthritis
NL2013007B1 (en) * 2014-06-16 2016-07-05 Ablynx Nv Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
US11278618B2 (en) * 2014-09-10 2022-03-22 Novartis Ag Use of IL-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients
ES2941234T3 (es) * 2014-10-22 2023-05-19 Armo Biosciences Inc Métodos de uso de la interleucina-10 para el tratamiento de enfermedades y trastornos
AR103173A1 (es) * 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
AU2016226415B2 (en) 2015-03-02 2021-09-09 180 Therapeutics Lp Method of treating a localized fibrotic disorder using a TNF receptor 2 antagonist
EP3167892A1 (en) 2015-11-10 2017-05-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for preventing or treating imflammatory bowel diseases
KR20180064415A (ko) * 2015-10-19 2018-06-14 노파르티스 아게 인터류킨-17 (il-17) 길항제를 사용하여 비-방사선촬영상 축성 척추관절염을 치료하는 방법
AU2017316513A1 (en) * 2016-08-23 2019-03-28 Csl Behring Gmbh Method of preventing acute attacks of hereditary angioedema associated with C1 esterase inhibitor deficiency
CN111344043A (zh) * 2017-11-02 2020-06-26 诺华股份有限公司 使用白细胞介素-17(il-17)拮抗剂治疗肌腱病的方法
GB201719447D0 (en) * 2017-11-23 2018-01-10 Ucb Biopharma Sprl Pharmaceutical composition
JP2021523894A (ja) * 2018-05-09 2021-09-09 ノバルティス アーゲー カナキヌマブの使用
EP3856770A4 (en) * 2018-09-26 2022-07-27 Viela Bio, Inc. CD40L ANTAGONIST AND ITS USES
EP3914250A1 (en) * 2019-01-22 2021-12-01 F. Hoffmann-La Roche AG Methods of treating rheumatoid arthritis, chronic spontaneous urticaria, and systemic lupus erythematosis using an inhibitor of bruton's tyrosine kinase
AU2020225202B2 (en) 2019-02-18 2023-10-26 Eli Lilly And Company Therapeutic antibody formulation
KR102169901B1 (ko) * 2019-05-17 2020-10-26 연세대학교 산학협력단 Dna 메틸화를 이용한 면역 항암 요법의 치료 반응에 관한 정보 제공 방법 및 이를 이용한 키트
CN110179746A (zh) * 2019-05-17 2019-08-30 通化东宝生物科技有限公司 一种稳定的苏金单抗注射剂及其制备方法
KR20220103141A (ko) 2019-11-19 2022-07-21 노파르티스 아게 인터류킨-17(il-17) 길항제를 사용하여 루푸스 신장염을 치료하는 방법
CN112915201B (zh) * 2019-12-06 2023-06-27 珠海市丽珠单抗生物技术有限公司 包含抗il-17抗体的液体制剂
WO2021146850A1 (en) * 2020-01-20 2021-07-29 Tsinghua University A critical role of febrile temperature in regulating interleukin (il) -17 producing cells via smad4
WO2022144023A1 (zh) * 2021-01-04 2022-07-07 江苏恒瑞医药股份有限公司 抗il-17抗体治疗自身免疫性疾病和炎症的方法
TW202246329A (zh) * 2021-03-03 2022-12-01 大陸商蘇州盛迪亞生物醫藥有限公司 抗il-17抗體治療自體免疫性疾病和炎症的方法
WO2022271544A1 (en) * 2021-06-21 2022-12-29 Bristol-Myers Squibb Company Use of sucrose, mannitol and glycine to reduce reconstitution time of high concentration lyophilized biologics drug products
CN114306594A (zh) * 2021-12-21 2022-04-12 华中科技大学同济医学院附属协和医院 地舒单抗在制备治疗膝关节骨性关节炎的药物中的应用

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0565233A (ja) 1991-03-08 1993-03-19 Mitsui Toatsu Chem Inc モノクローナル抗体含有凍結乾燥製剤
US5250442A (en) 1993-04-08 1993-10-05 Orestes Cabezas Method of treating rheumatoid arthritis using tetracycline
US6309636B1 (en) * 1995-09-14 2001-10-30 Cancer Research Institute Of Contra Costa Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US20050147609A1 (en) 1998-05-15 2005-07-07 Genentech, Inc. Use of anti-IL-17 antibody for the treatment of cartilage damaged by osteoarthritis
JP2000186046A (ja) 1998-10-14 2000-07-04 Snow Brand Milk Prod Co Ltd 慢性関節リウマチ治療剤及び診断方法
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
PT1133558E (pt) 1998-11-27 2007-01-31 Ucb Sa Composições e métodos para aumentar a mineralização óssea
WO2003009817A2 (en) 2001-07-25 2003-02-06 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
WO2003041637A2 (en) 2001-11-09 2003-05-22 Centocor, Inc. Lyophilized monoclonal antibody compositions
WO2003073991A2 (en) 2002-03-01 2003-09-12 Celltech R & D, Inc. Methods to increase or decrease bone density
WO2003106657A2 (en) 2002-06-14 2003-12-24 Stowers Institute For Medical Research Wise/sost nucleic acid sequences and amino acid sequences
US6974701B2 (en) 2003-03-21 2005-12-13 Hemovations, Llc Erythrocyte sedimentation rate (ESR) test measurement instrument of unitary design and method of using the same
CN1835974A (zh) 2003-06-16 2006-09-20 细胞技术研究与发展公司 对硬化素特异的抗体和用于增加骨矿化的方法
US8461155B2 (en) 2003-09-22 2013-06-11 University Of Connecticut Sclerostin and the inhibition of WNT signaling and bone formation
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
JP3936365B2 (ja) 2004-09-14 2007-06-27 ソニーケミカル＆インフォメーションデバイス株式会社 機能素子実装モジュール及びその製造方法
KR100996801B1 (ko) 2005-03-08 2010-11-25 파마시아 앤드 업존 캄파니 엘엘씨 항-ＭＡｄＣＡＭ 항체 조성물
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
WO2007056188A1 (en) 2005-11-04 2007-05-18 President And Fellows Of Harvard College Synthesis of inhibitors of ftsz
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
EP1977763A4 (en) 2005-12-28 2010-06-02 Chugai Pharmaceutical Co Ltd STABILIZER PREPARATION CONTAINING ANTIBODIES
US8012477B2 (en) * 2006-01-31 2011-09-06 Novartis Ag Methods of treating multiple myeloma using IL-17 binding molecules
TW200815469A (en) 2006-06-23 2008-04-01 Astrazeneca Ab Compounds
MX2009002418A (es) 2006-09-05 2009-04-23 Medarex Inc Anticuerpos para las proteinas morfogenicas oseas y receptores de estas y metodos para su uso.
WO2008029908A1 (fr) 2006-09-07 2008-03-13 Kyowa Hakko Kirin Co., Ltd. Préparation pharmaceutique lyophilisée stable comprenant un anticorps
CN101541833B (zh) * 2006-10-02 2014-01-29 麒麟-安姆根有限公司 Il-17受体a抗原结合蛋白质
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
WO2008061013A2 (en) 2006-11-10 2008-05-22 Amgen Inc. Antibody-based diagnostics and therapeutics
EP2094731A2 (en) 2006-11-10 2009-09-02 UCB Pharma S.A. Anti human sclerostin antibodies
JP2010526766A (ja) 2007-02-02 2010-08-05 ノバルティス アーゲー 骨関連障害を処置するためのスクレロスチン結合パートナーのモジュレーター
BRPI0809026A2 (pt) 2007-03-20 2014-09-23 Lilly Co Eli Anticorpos antiesclerotina
UA96473C2 (ru) 2007-03-22 2011-11-10 Имклоун Ллк Жидкая стойкая композиция, которая содержит антитело imc-а12
WO2008121615A2 (en) * 2007-03-30 2008-10-09 Medimmune, Inc. Antibody formulation
US20100239590A1 (en) * 2007-06-20 2010-09-23 Schering Corporation Joint destruction biomarkers for anti-il-17a therapy of inflammatory joint disease
US7720605B2 (en) 2007-06-22 2010-05-18 Weyerhaeuser Nr Company Identifying vegetation attributes from LiDAR data
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
AR068767A1 (es) 2007-10-12 2009-12-02 Novartis Ag Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
BRPI0819688A2 (pt) 2007-12-14 2015-06-16 Amgen Inc Processo para tratamento de fratura óssea com anticorpos anti-esclerostina.
EP3002299A1 (en) 2008-06-03 2016-04-06 AbbVie Inc. Dual variable domain immunoglobulins and uses thereof
KR20110031369A (ko) 2008-07-08 2011-03-25 아보트 러보러터리즈 프로스타글란딘 ｅ2 이원 가변 도메인 면역글로불린 및 이의 용도
AU2009296299A1 (en) 2008-09-29 2010-04-01 Roche Glycart Ag Antibodies against human IL 17 and uses thereof
EP2358392B1 (en) 2008-11-12 2019-01-09 MedImmune, LLC Antibody formulation
FR2938547B1 (fr) 2008-11-14 2012-11-16 Total Raffinage Marketing Liant synthetique clair
US20110256130A1 (en) 2008-12-01 2011-10-20 Joshua Robert Schultz Methods of treating inflammatory disorders
RU2015132478A (ru) 2009-03-05 2015-12-10 Эббви Инк. Связывающие il-17 белки
ES2733712T3 (es) * 2010-11-05 2019-12-02 Novartis Ag Métodos para tratar la espondilitis anquilosante utilizando anticuerpos anti-IL-17
AR084234A1 (es) * 2010-12-13 2013-05-02 Novartis Ag Metodos predictivos y metodos para tratar artritis usando antagonistas de interleuquina 17 (il-17)

Also Published As

Publication number Publication date
US20190307880A1 (en) 2019-10-10
AU2011325134A1 (en) 2013-04-04
EP2635303A2 (en) 2013-09-11
BR112013011176A2 (pt) 2020-09-01
US20210177966A1 (en) 2021-06-17
AU2011325134B2 (en) 2014-10-23
ES2733712T3 (es) 2019-12-02
JP2014503482A (ja) 2014-02-13
JP2016065094A (ja) 2016-04-28
US11534491B2 (en) 2022-12-27
IL262559B (en) 2022-06-01
KR20160067984A (ko) 2016-06-14
KR20140008305A (ko) 2014-01-21
HRP20191162T1 (hr) 2019-10-04
EP3542820A1 (en) 2019-09-25
JP6250109B2 (ja) 2017-12-20
IL225309B (en) 2021-05-31
JP2017002064A (ja) 2017-01-05
CL2013001213A1 (es) 2014-03-28
CA2813849C (en) 2021-06-15
TWI616204B (zh) 2018-03-01
JP6515168B2 (ja) 2019-05-15
WO2012059598A2 (en) 2012-05-10
KR20180129991A (ko) 2018-12-05
CA3116725C (en) 2023-10-24
JP2019142912A (ja) 2019-08-29
MX362591B (es) 2019-01-25
CY1121802T1 (el) 2020-07-31
JP2023109910A (ja) 2023-08-08
KR20150020734A (ko) 2015-02-26
SG189138A1 (en) 2013-05-31
US9744234B2 (en) 2017-08-29
WO2012059598A3 (en) 2012-09-27
CA2813849A1 (en) 2012-05-10
IL262559A (en) 2018-12-31
SG10201505624VA (en) 2015-09-29
DE20187001T1 (de) 2021-04-01
JP6049843B2 (ja) 2016-12-21
CA3116725A1 (en) 2012-05-10
PL3111954T3 (pl) 2019-10-31
EP3757126A1 (en) 2020-12-30
DK3111954T3 (da) 2019-07-15
US20130209480A1 (en) 2013-08-15
PT3111954T (pt) 2019-07-10
TW201306864A (zh) 2013-02-16
IL282625A (en) 2021-06-30
US20200276305A1 (en) 2020-09-03
IL225309A0 (en) 2013-06-27
RU2582937C2 (ru) 2016-04-27
JP2018065826A (ja) 2018-04-26
US20230293683A1 (en) 2023-09-21
HUE044038T2 (hu) 2019-09-30
CN103189074A (zh) 2013-07-03
JP2021104995A (ja) 2021-07-26
TW201726170A (zh) 2017-08-01
TW201517917A (zh) 2015-05-16
SI3111954T1 (sl) 2019-08-30
EP4116325A1 (en) 2023-01-11
TWI618543B (zh) 2018-03-21
US20220193234A1 (en) 2022-06-23
MX2013005060A (es) 2013-06-28
US20180008706A1 (en) 2018-01-11
US20210128726A1 (en) 2021-05-06
MA34647B1 (fr) 2013-11-02
KR20180019247A (ko) 2018-02-23
TR201909531T4 (tr) 2019-07-22
CN104800844A (zh) 2015-07-29
US10363307B2 (en) 2019-07-30
EP3111954B1 (en) 2019-04-03
EP3912640A1 (en) 2021-11-24
TWI604851B (zh) 2017-11-11
EP3111954A1 (en) 2017-01-04
US20230346926A1 (en) 2023-11-02
ES2804624T1 (es) 2021-02-08
IL311014A (en) 2024-04-01
RU2013125775A (ru) 2014-12-10

Similar Documents

Publication Publication Date Title
LT3111954T (lt) Ankilozuojančio spondilito gydymo būdai, naudojant anti-il-17 antikūnus
HRP20181360T1 (hr) Anti-cd28 humanizirana protutijela
PT2768857T (pt) Métodos para purificar anticorpos
IL221288A0 (en) Therapeutic methods using anti-cd200 antibodies
HK1195320A1 (en) Antibodies for treatment of cancer expressing claudin
IL229254A0 (en) Therapeutic antibodies
IL249501B (en) A process for creating antibodies
HK1182625A1 (en) Bispecific antibodies
EP2658970A4 (en) EXPRESS HUMANIZATION OF ANTIBODIES
ZA201403108B (en) Purification of anti-c-met antibodies
EP2668206A4 (en) GENETIC MODIFICATION OF DOMAINS OF IMMUNOGLOBULINS
EP2542258A4 (en) MONOCLONAL ANTIBODIES DIRECTED AGAINST CD52
SG11201400405TA (en) Caninised antibodies and method for the production of same
HK1201537A1 (en) Anti-kdr antibodies and methods of use -kdr
EP2616812A4 (en) METHOD FOR TREATING AUTOIMMUNE DISEASES WITH ANTI-FCERI ANTIBODIES
EP2714713A4 (en) PURIFICATION OF ANTIBODIES
GB201020045D0 (en) Method for the treatment of biogas
HK1184173A1 (en) Anti-kdr antibodies and methods of use -kdr
IL226040A0 (en) Methods for generating antibodies to metalloenzymes
ZA201308992B (en) Therapeutic antibodies